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may benefit from Se supplementation. Dietary 
Se intake varies worldwide from 7 μg to 4990 μg 
per day. The mean value in Europe is 40 μg per 
day and in the United States, 93 μg per day (in 
women) to 134 μg per day (in men). Nutritional 
products that are rich in Se are Brazil nuts, of‑
fal, seafood, cereals, and grains.1‑4
Oxidative stress caused by the insufficient an‑
tioxidant dietary intake and improper balance 
INTRODUCTION Selenium (Se) is a micronutri‑
ent important for human health. It is incorporat‑
ed as selenocysteine at the active site of 25 sele‑
noproteins, for example, glutathione peroxidase 
(GPX), iodothyronine deiodinases, selenoprotein 
P, thioredoxin reductase, selenoprotein S, and 
other. Due to the U ‑shaped dose ‑response rela‑
tionship, toxic concentrations of Se may be harm‑
ful, which is why only people with low Se levels 
Correspondence to: 
Andrzej Gackowski, MD, PhD, 
Department of Coronary 
Disease and Heart Failure, 











BACKGROUND Selenium (Se) is incorporated in 25 enzymes, for example, glutathione peroxidase (activated 
by oxidative stress) and deiodinases (converting thyroid hormones). Oxidative stress present in heart 
failure (HF) and myocardial infarction (MI) might cause Se deficiency and decreased thyroxine 
to triiodothyronine conversion.
AIMS We sought to evaluate Se levels in Polish patients with MI, HF, and healthy volunteers in relation 
to thyroid hormone levels.
METHODS The study group consisted of 143 participants: 54 patients with MI, 59 patients with 
decompensated HF, and 30 healthy matched volunteers. The patients underwent echocardiography and 
laboratory tests on admission and 5 months later.
RESULTS Selenium levels were lower in patients with MI and HF than in controls (median [interquartile 
range, IQR], 65.9 [55.2–76.1] µg/l and 59.7 [47.7–70.7] µg/l vs 93.2 [84.2–99.1] µg/l, respectively; P <0.001). 
The Se deficiency was very common in patients with MI and HF, while it was rare in controls (70.37% and 
74.58% vs 10%, respectively; P <0.001). Patients with MI and HF presented lower free triiodothyronine 
(FT3) levels and lower FT3 to free thyroxine (FT4) ratio in comparison with controls (median [IQR], 
3.90  [3.60–4.38] pmol/l and 4.25 [3.57–4.60] pmol/l vs 4.92 [4.50–5.27] pmol/l; P <0.001; and 0.25 
[0.23–0.29] and 0.25 [0.21–0.28] vs 0.32 [0.29–0.37]; P <0.001, respectively). There was a weak to moderate 
correlation between Se level, FT3 level, and the FT3/FT4 ratio. At follow ‑up, the FT3/FT4 ratio tended to 
normalize in patients with MI and remained decreased in patients with HF (mean [SD], 0.31 [0.06] vs 0.27 
[0.05]; P <0.001).
CONCLUSIONS Selenium deficiency is very common in Polish patients with MI and HF. Thyroid hormones 
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Polish patients with MI, HF, and healthy volun‑
teers in relation to thyroid hormone levels. We 
also evaluated the clinical course of MI and HF 
in subgroups with normal or lowered Se levels.
METHODS Study population The protocol 
of this prospective cohort study was approved 
by the local ethics committee. All study proce‑
dures performed involving human participants 
were in accordance with the ethical standards 
of the Declaration of Helsinki. Between June 
2015 and August 2017, we prospectively evalu‑
ated 113 consecutive inpatients and 30 healthy 
volunteers who expressed their written informed 
consent and met the inclusion / exclusion crite‑
ria, which were as follows:
1	 The MI group included patients with acute ST‑
‑segment elevation MI or non–ST ‑segment eleva‑
tion MI, treated with primary percutaneous cor‑
onary intervention.21 The exclusion criteria were 
known HF, thyroid disease, treatment with ami‑
odarone, glucocorticoids, or propranolol, as well 
as clinical evidence of severe systemic disease 
such as inflammatory, autoimmune, neoplas‑
tic, or chronic renal disease (estimated glomer‑
ular filtration rate [eGFR] <30 ml/min/1.73 m2).
2	 The HF group included patients with de‑
compensated HF with reduced ejection frac‑
tion.16 The exclusion criteria were acute coro‑
nary syndrome, thyroid disease, treatment 
with amiodarone, glucocorticoids, or propran‑
olol, as well as clinical evidence of severe sys‑
temic disease such as inflammatory, autoim‑
mune, neoplastic, or chronic renal disease (eGFR 
<30 ml/min/1.73 m2).
3	 The C group (control group) included healthy 
volunteers with normal electrocardiogram 
matched for sex and age.
All patients with MI and HF received opti‑
mal guideline‑directed medical treatment.16,21 
Depending on the Se concentration, additional 
4 subgroups were identified in the MI and HF 
groups: MI ‑A and HF ‑A subgroups including 
patients with Se concentration below the nor‑
mal values and with MI or HF, respectively, as 
well as MI ‑B and HF ‑B subgroups including pa‑
tients without decreased Se levels and with MI 
or HF, respectively.
Biochemical tests Single blood samples 
were collected for thyroid profiles and Se in 
the C group. Serial blood samples were collect‑
ed in MI and HF groups.
On the first and third day of hospitaliza‑
tion and at the follow ‑up visit, the patients had 
the following laboratory tests performed: thy‑
roid stimulating hormone (TSH; electrochemi‑
luminescence immunoassay [ECLIA] method), 
free thyroxine (FT4), and free triiodothyronine 
(FT3; ECLIA method). Then, the FT3/FT4 ratio 
was calculated. The reverse triiodothyronine 
between prooxidant and antioxidant enzymes, 
leading to an excess of reactive oxygen species, 
may be associated with cardiovascular diseases.5 
It has been proven that low GPX activity can be 
used to identify patients at high cardiovascular 
risk.6,7 As Se levels correlate positively with en‑
zymatic activity and protein levels of GPX, Se 
plasma analysis may be used for an indirect as‑
sessment of oxidative stress.8,9 GPX and Se de‑
ficiency may exacerbate endothelial dysfunc‑
tion, low ‑density lipoprotein cholesterol oxida‑
tion, atherosclerosis, myocardial susceptibility 
to ischemia and reperfusion injury, as well as 
impaired thyroid hormone conversion. These 
phenomena may contribute to subsequent heart 
failure (HF).9‑13
A prospective epidemiological study conduct‑
ed in Finland revealed that the serum Se con‑
centration was inversely related to the risk 
of myocardial infarction (MI) and cardiovas‑
cular death.14 Another study conducted in New 
Zealand showed that a decrease in blood lev‑
el of Se in cigarette smokers is a risk factor for 
coronary heart disease.15 Se deficiency is men‑
tioned in the current European Society of Car‑
diology guidelines for the diagnosis and treat‑
ment of acute and chronic HF as a nutritional 
cause of the disease.16 Se deficiency is a possible 
risk factor for Keshan disease, which is an en‑
demic cardiomyopathy in Se ‑poor areas of Chi‑
na.17 Even in Se ‑rich areas, HF caused by Se de‑
ficiency may be a result of malnutrition occur‑
ring in patients with HIV, gastrointestinal dis‑
eases, parenteral nutrition or in those after bar‑
iatric surgery.18‑20
Because selenoproteins (GPX and iodothyro‑
nine deiodinases) may compete for Se, oxida‑
tive stress causing Se deficiency may contribute 
to disturbances of thyroid hormone conversion. 
These conditions alone and collectively may affect 
the cardiovascular system. Lifestyle, diet, and 
smoking habits differ from country to country 
and may influence Se levels. To our knowledge, 
Se levels have not been studied in the context 
of thyroid function in patients with cardiovas‑
cular disease in Poland. The main purpose of our 
study was, therefore, to evaluate Se levels in 
WHAT’S NEW?
The function of deiodinases (thyroid hormone converting enzymes) may be 
disturbed by oxidative stress accompanying heart failure (HF) or myocardial 
infarction (MI), because both deiodinases and glutathione peroxidase (an 
antioxidant enzyme) are selenoproteins competing for selenium (Se). Our 
research revealed that Se deficiency is very common in Polish patients with 
MI or HF. They also present with lower free triiodothyronine levels and lower 
free triiodothyronine to free thyroxine ratio. We noticed that thyroid hormones 
disturbances are transient in acute MI, but chronic in HF. There is a mild ‑to‑
‑moderate correlation between Se and thyroid hormone levels. Further studies 
are needed to investigate whether Se deficiency contributes to HF progression. 
They may provide the rationale to support Se supplementation in HF.
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6 hours during the first 24 hours. Normal val‑
ues of hsTnT, CK ‑MB and CK were <0.014 ng/ml, 
0–24 U/l, and 0‑190 U/l, respectively.
Biochemical tests were performed using 
the Roche Diagnostics GmbH (Mannheim, Ger‑
many) kits. Full blood count was performed us‑
ing the Sysmex Corporation (Kobe, Japan) kits.
Blood samples for Se serum assays were taken 
on the third day of hospitalization. After collec‑
tion, blood samples were left to clot for 30 min‑
utes and were centrifuged afterwards (1300G, 12 
minutes). Serum samples were frozen at –80°C 
(–112°F). On the day of analysis, samples were 
centrifuged (5000G, 5 minutes). Inductively cou‑
pled plasma mass spectrometry was used in the 
analyses. Se determination was performed on 
an inductively coupled plasma mass spectrom‑
eter NexION 350D (PerkinElmer, Shelton, Con‑
necticut, United States). The spectrometer was 
equipped with a dynamic reaction cell operat‑
ing with high purity methane. It was calibrated 
using an external calibration technique. Cali‑
bration standards were prepared from 10 µg/
(rT3) level was determined using the  radio‑
isotope method on the third day of hospital‑
ization. Laboratory reference values for THS, 
FT3, FT4, and rT3 were 0.27–4.2 µIU/ml, 3.10–
6.80  pmol/l, 12.0–22.0  pmol/l, and 0.09–
0.35 ng/ml, respectively.
The N ‑terminal pro ‑B‑type natriuretic peptide 
(NT ‑proBNP) (ECLIA method) levels were deter‑
mined on the first and third day of hospitaliza‑
tion and at the follow ‑up. The reference value for 
NT ‑proBNP was <125.0 pg/ml. The inflammato‑
ry markers, high ‑sensitivity C ‑reactive protein 
(hs ‑CRP) (immunoturbodimetric method) and 
white blood count (WBC) (hydrodynamic focus‑
ing method in flow cytometry), were determined 
on the first and third day of hospitalization. Cre‑
atinine levels (Jaffé Gen. 2 method, rate blanked, 
compensated) and eGFR using the CKD ‑EPI for‑
mula were assessed at admission.
In MI group, serum levels of high sensitivity 
troponin T (hsTnT), creatinine kinase MB (CK‑
‑MB), and creatinine kinase (CK) (ECLIA method) 
were measured at admission and repeated every 
TABLE 1 Characteristics of the whole group of patients with myocardial infarction and its subgroups according to selenium concentration
Parameter MI group (n = 54) MI ‑A subgroup (n = 38) MI ‑B subgroup (n = 16) P value
Sea, µg/l 66.73 (14.56) 60.24 (10.93) 82.13 (9.72) <0.001
Age, y 60.41 (8.91) 60.11 (9.55) 61.13 (7.38) 0.70
Male sex, n (%) 47 (87.04) 34 (89.47) 13 (81.25) 0.41
BMI, kg/m2 26.2 (24.8–30.8) 26.7 (24.4–30.6) 26.2 (24.8–32.3) 0.76
STEMI, n (%) 41 (75.93) 27 (71.05) 14 (87.50) 0.30
NSTEMI, n (%) 13 (24.07) 11 (28.95) 2 (12.50)
hsTnT (max), ng/ml 4.09 (0.96–6.30) 4.09 (0.94–5.62) 3.50 (0.90–6.81) 0.91
TSHb, µIU/ml 1.12 (0.72–1.59) 1.11 (0.74–1.54) 1.13 (0.64–1.72) 0.87
FT3b, pmol/l 4.21 (3.86–4.71) 4.30 (3.90–4.82) 3.90 (3.77–4.38) 0.21
FT4b, pmol/l 15.96 (2.27) 16.00 (2.47) 15.85 (1.77) 0.82
FT3/FT4 ratiob 0.26 (0.24–0.30) 0.26 (0.23–0.30) 0.26 (0.24–0.30) 0.73
rT3a, ng/ml 0.20 (0.13–0.28) 0.22 (0.14–0.28) 0.18 (0.12–0.21) 0.14
NT ‑proBNPa, pg/ml 809.0 (385.5–1385.6) 809.0 (460.3– 1489.5) 667.5 (106.5–1263.5) 0.29
hs ‑CRPb, mg/l 6.98 (3.17–12.38) 6.68 (2.40–11.88) 7.86 (4.97–13.65) 0.35
WBCb, ×109/l 11.41 (3.24) 11.52 (3.79) 1.17 (1.28) 0.62
WBCa, ×109/l 8.87 (2.35) 9.36 (2.41) 7.69 (1.73) 0.02
eGFR, CKD ‑EPIb 78.06 (16.72) 79.61 (17.32) 74.38 (15.08) 0.30
LVEDV, ml 111.50 (92.75–143.50) 114.50 (92.75–148.00) 105.50 (91.65–145.00) 0.42
LVEF, % 52.63 (10.31) 52.08 (11.12) 53.94 (8.27) 0.55
Data are presented as mean (SD) or median (interquartile range) unless indicated otherwise.
a Measured on the third day of hospitalization;  b  measured on the first day of hospitalization
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; FT3, free triiodothyronine; FT4, free thyroxine; hs ‑CRP, high ‑sensitivity C ‑reactive protein; 
hsTnT, high ‑sensitivity troponin T; LVEDV, left ventricular end ‑diastolic volume; LVEF, left ventricular ejection fraction; MI group, myocardial infarction group; NSTEMI, 
non–ST ‑segment elevation myocardial infarction; MI ‑A subgroup, myocardial infarction subgroup with Se below normal values; MI ‑B subgroup, myocardial infarction 
subgroup with normal Se values; NT ‑proBNP, N ‑terminal pro B ‑type Natriuretic Peptide; rT3, reverse triiodothyronine; Se, selenium; STEMI, ST ‑segment elevation 
myocardial infarction; TSH, thyroid stimulating hormone; WBC, white blood count
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and at  follow ‑up (Philips IE33, Amsterdam, 
the Netherlands) by the same echocardiogra‑
pher with a blind review and confirmation by an‑
other echocardiographer. The following parame‑
ters were analyzed: left ventricular end ‑diastolic 
diameter and volume, left ventricular ejection 
fraction (LVEF), left ventricular filling profile, 
E/E’ index, tricuspid annular plane systolic ex‑
cursion, and right ventricular systolic pressure.
Study endpoints Major adverse cardiovascu‑
lar events in the MI and HF groups included re‑
suscitated cardiac arrest, cardiovascular death, 
rehospitalization for HF decompensation requir‑
ing intravenous diuretics and/or catecholamines, 
evidence of ventricular tachycardia, severe sinus 
bradycardia, or atrioventricular blocks.
Each event was analyzed during the hospital 
stay and during the follow ‑up of median (IQR) 
154.0 (132.8–168.8) and 144.0 (123.0–161.0) days 
in the MI and HF group, respectively. The com‑
posite endpoint of the above adverse events was 
also analyzed.
Statistical analysis Categorical variables 
were presented as numbers and percentag‑
es. Continuous variables were expressed as 
mean (SD) or median and interquartile ranges 
ml Multielement Calibration Standard 3. Cor‑
relation coefficients for calibration curves were 
always greater than 0.999. The analysis proto‑
col assumed 100‑fold dilution of serum in a re‑
agent blank. The reagent blank consisted of 10 ml 
of 65% Suprapur Grade (Merck, Darmstadt, Ger‑
many) nitric acid, 0.20 ml of Triton X‑100 (Perki‑
nElmer) filled to the mark of a 1 liter flask with 
class I deionized water (Merck Millipore). Ger‑
manium isotope, Ge74, was set as an internal 
standard.
The  quality of  Se determination was ver‑
ified with the use of reference material Clin‑
check Plasmonorm Serum Trace Elements Lev‑
el 1 (RECIPE Chemicals + Instruments GmbH, 
Munich, Germany). Se reference levels were es‑
tablished in the group of 2500 women and 1600 
men from the Polish population. The follow‑
ing reference values of Se levels were used by 
the local laboratory: 75.0–85.0 µg/l and 65.0–
75.0 µg/l for women younger than 50 and old‑
er than 50 years of age, respectively; 85.0–95.0 
µg/l and 70.0–90.0 µg/l for men younger than 
60 and older than 60 years of age, respectively.
Echocardiographic assessment A transtho‑
racic echocardiographic evaluation of the left 
ventricle was performed during hospitalization 
TABLE 2 Characteristics of the whole group of patients with heart failure and its subgroups according to selenium concentration
Parameter HF group (n = 59) HF ‑A group (n = 44) HF ‑B group (n = 15) P value
Sea, µg/l 59.74 (47.73– 70.66) 52.17 (45.01–60.43) 81.08 (74.85–86.80) <0.001
Age, y 65.0 (59.0–74.0) 64.0 (56.25–73.25) 67.00 (62.0–77.0) 0.19
Male sex, n (%) 48 (81.36) 38 (86.36) 10 (66.67) 0.13
BMI, kg/m2 28.4 (25.5–32.3) 28.9 (25.6–33.3) 28.1 (24.9–31.0) 0.35
TSHb, µIU/ml 1.54 (0.93–2.05) 1.52 (0.91–2.16) 1.56 (1.06–2.01) 0.90
FT3b, pmol/l 4.16 (0.94) 4.05 (0.89) 4.51 (1.01) 0.10
FT4b, pmol/l 17.95 (2.98) 17.70 (2.77) 18.66 (3.53) 0.29
FT3/FT4 ratiob 0.24 (0.06) 0.23 (0.06) 0.24 (0.06) 0.49
rT3a, ng/ml 0.21 (0.09) 0.23 (0.09) 0.17 (0.08) 0.03
NT ‑proBNPb, pg/ml 3478.0 (1888–6837) 2989.5 (1870–7011) 4029.0 (1909–5922) 0.88
hs ‑CRPb, mg/l 4.77 (1.90–9.83) 6.73 (1.93–10.29) 2.75 (1.62–7.10) 0.20
WBCb, ×109/l 7.81 (6.05–9.45) 8.02 (6.01–9.41) 7.40 (6.32–9.45) 0.99
eGFR, CKD ‑EPIb 65.90 (18.92) 64.40 (17.73) 70.20 (22.06) 0.31
LVEDV, ml 234.47 (86.11) 230.43 (81.77) 246.33 (99.93) 0.54
LVEF, % 23.96 (7.92) 24.36 (8.00) 22.80 (7.81) 0.51
Number of patients with 
restrictive mitral filling 
patternc, n (%)
18d (52.94) 15e (65.22) 3f (27.27) 0.04
Data are presented as mean (SD) or median (interquartile range) unless indicated otherwise.
a Measured on the third day of hospitalization;  b  measured on the first day of hospitalization;  c  patients with atrial fibrillation were excluded from this analysis; 
d n = 34;  e n = 23; f n = 11
Abbreviations: HF group, heart failure group; HF ‑A subgroup, heart failure subgroup with Se below normal values; HF ‑B subgroup, heart failure subgroup with normal Se 
values; others, see TABLE 1
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rank correlation coefficient, depending on nor‑
mality. The statistical analyses were performed 
with JMP® version 14.0.0 software (SAS Institute 
INC., Cary, North Carolina, United States) and 
R version 3.4.1 software (R Core Team. R: A lan‑
guage and environment for statistical comput‑
ing. R Foundation for Statistical Computing. Vi‑
enna, Austria, 2017). A P value of less than 0.05 
was considered significant.
RESULTS The characteristics of the MI and HF 
groups as well as subgroups identified based on 
Se concentration are presented in TABLE 1 and TABLE 2.
There was no difference in age, sex, body mass 
index (BMI), MI type, culprit coronary artery, 
as well as prevalence of hypertension, diabetes 
mellitus, dyslipidemia, and smoking between 
the MI ‑A and MI ‑B subgroups. Furthermore, 
subgroups did not differ with regards to the fol‑
lowing laboratory tests: hsTnT, CK ‑MB, CK, NT‑
‑proBNP, hs ‑CRP, eGFR, TSH, thyroid hormones, 
and all analyzed echocardiographic parameters. 
(IQR). The normality of distribution was as‑
sessed using the Shapiro –Wilk test. The equal‑
ity of variances was assessed using the Levene 
test. The between ‑group differences were deter‑
mined using the t test or Welch t test depending 
on the equality of variances for normally distrib‑
uted variables. The Mann–Whitney test was used 
for nonnormally distributed continuous vari‑
ables. Categorical variables were compared us‑
ing the Pearson χ2 test or the Fisher exact test if 
20% of cells had an expected count of less than 5. 
For 2 paired data samples, the 2‑tailed t test was 
used if differences between pairs were normal‑
ly distributed, and the Wilcoxon signed ‑rank if 
they were not normally distributed. For more 
than 2 measurements, the repeated measures 
ANOVA was used. Post hoc analyses were made 
using the  Tukey–Kramer HSD for indepen‑
dent samples or the Steel–Dwass method, for 
paired samples. The P values were adjusted us‑
ing the Bonferroni correction. The correlations 
between the variables were determined using 
the Pearson’s correlation coefficient or Spearman 
TABLE	3 Comparison of patients with myocardial infarction, heart failure, and control group
Characteristics MI group (n = 54) HF group (n = 59) C group (n = 30) P value
Age, y 61.0 (53.8–67.3) 65.0 (59.0–74.0) 61.5 (57.5–68.8) 0.08
Male sex, n (%) 47 (87.04) 48 (81.36) 25 (83.33) 0.71
Smoking, n (%) 33 (61.11) 21 (35.59) 8 (27.59) 0.004a,b
BMI, kg/m2 26.2 (24.8–30.79) 28.4 (25.5–32.3) 30.1 (27.4–34.8) 0.01b
SBP, mm Hg 153.0 (137.0–167.3) 123 (111–138) 140.5 (123–155) <0.001a,c
DBP, mm Hg 91.9 (13.1) 80.8 (15.0) 84.1 (13.3) <0.001a,b
Se, µg/l 65.9 (55.2–76.1) 59.7 (47.7–70.6) 93.2 (84.2–99.1) <0.001b,c
Se deficiency, n (%) 38 (70.37) 44 (74.58) 3 (10.00) <0.001b,c
First day of hospitalization TSH, µIU/ml 1.12 (0.72–1.59) 1.54 (0.93–2.05) 1.08 (0.68–1.80) 0.01a,c
FT3, pmol/l 4.21 (0.69) 4.16 (0.94) 4.99 (0.66) <0.001b,c
FT4, pmol/l 15.96 (2.27) 17.95 (2.98) 15.31 (1.91) <0.001a,c
FT3/FT4 ratio 0.27 (0.04) 0.24 (0.06) 0.33 (0.05) <0.001a,b,c
Third day of hospitalization TSH, µIU/ml 2.23 (1.20–3.11) 1.60 (1.16–2.03) 1.08 (0.68–1.80) <0.001b,c
FT3, pmol/l 3.90 (3.60–4.38) 4.25 (3.57–4.60) 4.92 (4.50–5.27) <0.001b,c
FT4, pmol/l 5.33 (2.07) 17.40 (2.57) 15.31 (1.91) <0.001a,c
FT3/FT4 ratio 0.25 (0.23–0.29) 0.25 (0.21–0.28) 0.32 (0.29–0.37) <0.001b,c
Follow ‑up TSH, µIU/ml 1.21 (0.95–1.66) 1.48 (1.08–2.10) 1.08 (0.68–1.80) 0.047
FT3, pmol/l 4.99 (4.50–5.28) 4.66 (4.10–4.96) 4.92 (4.50–5.27) 0.03
FT4, pmol/l 16.35 (2.60) 17.41 (2.66) 15.31 (1.91) 0.002c
FT3/FT4 ratio 0.31 (0.06) 0.27 (0.05) 0.33 (0.05) <0.001a,c
Prevalence of low T3, n (%) 7 (12.96) 9 (15.25) 0 (0.00) 0.08
Data are presented as mean (SD) or median (interquartile range) unless indicated otherwise.
a P <0.05 MI group vs HF group;  b P <0.05 MI group vs C group;  c P <0.05 HF group vs C group
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure; others, see TABLE 1
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However, the patients in the MI ‑A subgroup had 
a significantly higher WBC count on the third 
day of hospitalization as compared with patients 
from the MI ‑B subgroup.
We demonstrated that patients from the HF‑
‑A subgroup presented with higher rT3 levels and 
more often had a restrictive mitral filling pat‑
tern in comparison with patients from the HF‑
‑B subgroup. There was no difference in age, sex, 
BMI, prevalence of hypertension, diabetes melli‑
tus, dyslipidemia, smoking, and HF etiology be‑
tween the HF ‑A and HF ‑B subgroups. Similarly, 
there was no difference in the NT ‑proBNP, hs‑
‑CRP, WBC, eGFR, TSH, FT3, FT4, levels, FT3/FT4 
ratio and the echocardiographic parameters be‑
tween the HF ‑A and HF ‑B subgroups.
There was no difference in the incidence of any 
individual major adverse cardiovascular event 
(P >0.05 for each predefined endpoint) or in 
the composite endpoint of all adverse events 
(P >0.05) between MI ‑A and HF ‑A subgroups 
in comparison with MI ‑B and HF ‑B subgroups.
The comparison of MI, HF, and C groups is 
presented in TABLE 3. There were no differences in 
age and sex between groups. The studied groups 
differed with respect to BMI and blood pres‑
sure. The Se deficiency was found in the major‑
ity of participants from MI and HF groups, but 
only the minority of participants in the control 
group. Furthermore, the Se levels were lower 
in both MI and HF groups in comparison with 
the controls (TABLE 3, FIGURE 1).
The between ‑group differences were shown in 
the TSH, FT3, and FT4 levels as well as the FT3/
FT4 ratio (TABLE 3, FIGURE 2). There were within ‑group 
differences in FT3 levels and FT3/FT4 ratio chang‑
es in both MI and HF groups (FIGURE 3). There was 
also a dynamic change of TSH concentration dur‑
ing the acute phase of MI and its normalization 
during follow ‑up (FIGURE 3).
Correlation analysis including Se, TSH, and 
TH levels is presented in TABLE 4 and FIGURE 4. There 
were weak correlations between Se, FT3, and 
FT4. Moderate correlations were found between 
Se and FT3/FT4 ratio. There was no correlation 
between Se and other clinical variables includ‑
ing LVEF, hsT, CK, CKMB, NT ‑proBNP, creati‑
nine, WBC, or hs ‑CRP.
DISCUSSION Our study showed that Se lev‑
els were lower in both patients with MI and 
chronic HF in comparison with healthy con‑
trols. Previously published research yielded 
inconclusive results. De Lorgeril et al22 dem‑
onstrated low dietary intake and blood Se lev‑
els in French patients with chronic HF. Simi‑
larly, Kosar et al23 from Turkey demonstrated 
that both dilated idiopathic and ischemic car‑
diomyopathy were associated with lower Se lev‑
els. Conversely, the study by Ghaemian et al24 
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FIGURE 1 Selenium plasma levels in patients with myocardial infarction, heart failure, and 
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FIGURE 2 Thyroid stimulating hormone levels, free triiodothyronine levels, and free 
triiodothyronine to free thyroxine ratio measured on the third day of hospitalization in patients with 
myocardial infarction and heart failure in comparison with controls. For medians (interquartile 
ranges), see TABLE 3. Abbreviations: see TABLE 1
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areas. The Mediterranean diet in Northern Iran 
is rich in Se, which may explain high Se levels 
found in both HF patients and healthy controls 
in the discussed study.22,24
We did not find correlations between Se and 
clinical variables reflecting disease severity in 
the present study. Previously, Se levels were 
found to be positively correlated with serum CK 
activity, serum myoglobin, and maximum tropo‑
nin levels.25,28,29 Another study revealed that Se 
may play a role in the clinical severity of HF (as‑
sessed by peak exercise oxygen consumption),22 
rather than in the degree of left ventricular dys‑
function.22‑24 However, the results are inconclu‑
sive because some previous studies found a pos‑
itive correlation between Se levels and LVEF 
in HF, and coronary artery disease.30‑32,28 Never‑
theless, sample sizes of the above study groups 
were very limited.
The presented findings suggest that Se levels 
may be lowered in both acute and chronic car‑
diac disorders. Further studies are needed as it 
is not clear whether the Se deficiency contrib‑
utes to disease progression or is merely a mark‑
er of its severity. Furthermore, the data on Se 
supplementation and its possible positive effect 
on clinical variables is very limited and not fo‑
cused on Se alone, as multiple micronutrients 
taken together were studied instead. It is also 
important that in studies of Se supplementation, 
baseline and target Se levels were not clearly de‑
fined, despite a known possibly harmful effect 
of Se overdose.33‑35
There is growing evidence that oxidative 
stress and thyroid function are significant fac‑
tors in HF development, while GPX levels corre‑
late with Se concentrations. We sought to check 
the relationship between the Se and thyroid 
hormone levels and only found a weak correla‑
tion; however, a moderate correlation between 
Se level and FT3/FT4 ratio was found. It would 
be of interest to investigate the causality of this 
relationship.
Our results showed between ‑group differ‑
ences in thyroid profiles. Patients with MI and 
HF presented with lower FT3 levels in compar‑
ison with the controls. Patients with MI pre‑
sented with dynamic TSH and FT3 changes over 
the first 3 days of hospitalization. Similar find‑
ings were reported by Friberg et al36 who dem‑
onstrated a rapid down ‑regulation of thyroid 
hormones in acute MI.
Low T3 syndrome and a decreased FT3/FT4 ra‑
tio were previously shown to be prognostic pre‑
dictors of death in patients with heart diseas‑
es.37,38 Our data indicates a difference in T4 to T3 
conversion between acute and chronic conditions. 
Furthermore, whereas there was no difference 
in the FT3/FT4 ratio between the MI and control 
groups at follow ‑up, the HF group had a lower 
FT3/FT4 ratio than the control group. These find‑
ings suggest that changes of the FT3/FT4 ratio 
these results.24 Lower Se concentrations were 
previously found in patients with myocardial 
infarction.15,25 ‑27 Discrepancies found in vari‑
ous studies might have been caused by differ‑
ences in Se intake in distinctive geographical 
TABLE 4 Correlations between the levels of selenium, thyroid‑stimulating 
hormone, and thyroid hormones
Variable By variable Correlation P value
Se TSH –0.1427 0.09
Se FT3 0.3900 <0.001
Se FT4 –0.2136 0.01























































 FIGURE 3  Changes of thyroid stimulating hormone and free triiodothyronine levels, and free 
triiodothyronine to free thyroxine ratio over time in patients with myocardial infarction and heart 
failure; for means (SD) or medians (interquartile ranges), see TABLE 3. Abbreviations: see TABLE 1
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We mainly sought to evaluate the Se and thy‑
roid status in both groups and compare it to 
that of controls. The study sample was not cal‑
culated to enable an analysis of hard endpoints, 
therefore the value of clinical event rate assess‑
ment is limited. The control group was selected 
so as to have similar demographic characteris‑
tics as the study groups; however, the BMI me‑
dian in the control group was above the normal 
range, which is a disadvantage of our research. 
The study was intended to show a real ‑life group 
of patients with HF and MI, which is why we did 
not exclude smokers, although smoking may 
influence the Se levels. For the same reason 
we did not exclude smokers from the control 
group to ensure the groups were comparable.
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are more dynamic and transient in MI than in 
HF, which is a chronic condition.
Although we were able to find articles 
on Se deficiency and thyroid hormone distur‑
bances in HF and MI patients, there are no stud‑
ies involving both conditions together. Lima et 
al39 did not find a correlation between Se and 
thyroid hormone levels in HF and concluded 
that there is a possible link between hypothy‑
roidism, but not micronutrient levels, and the se‑
verity of HF. However, in our research not only 
did we demonstrate lower Se levels and thyroid 
hormones disturbances in study groups, but we 
also found a correlation between them. Perhaps 
there is a relationship between these phenome‑
na. In our opinion, further research focused on 
Se levels, Se ‑dependent enzymes, and their in‑
fluence on the course of cardiovascular diseas‑
es, especially HF, is needed.
In conclusion, Se levels in patients with both 
acute MI and HF are lower than in healthy vol‑
unteers. The Se deficiency is highly prevalent 
in acute MI as well as both acute and chron‑
ic HF. The correlation between Se and thy‑
roid hormone levels was found to be weak to 
moderate.
Further research on Se deficiency in relation 
to oxidative stress markers and thyroid hormone 
conversion disturbances in patients with car‑
diovascular diseases, particularly HF, is need‑
ed. The potential role of Se deficiency in HF pro‑
gression should also be studied to verify wheth‑
er there are possible benefits of Se supplemen‑
tation in these patients.
Study limitations Patient enrolment and 
conducting the research of decompensated HF 
or acute MI with strict entry criteria are diffi‑
cult. As a result, the sample size was limited. 
FIGURE 4 Correlation between the levels of selenium, free triiodothyronine, and free triiodothyronine to free thyroxine ratio, measured on the third 
day of hospitalization Abbreviations: see TABLE 1
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